阿帕替尼治疗晚期肺腺癌患者的临床疗效

Clinical efficacy of apatinib in the treatment of advanced lung adenocarcinoma

目的探讨晚期肺腺癌患者采用阿帕替尼治疗的临床效果及用药安全性。方法选取2016年7月至2018年6月间江苏省溧阳市人民医院收治的110例晚期肺腺癌患者,采用阿帕替尼治疗的58例患者纳入观察组,采用最佳支持治疗的52例患者纳入对照组。比较两组患者的临床效果及用药安全性。结果观察组患者临床总有效率和疾病控制率分别为13. 8%和58. 6%,均高于对照组患者的0和13. 4%,差异均有统计学意义(均P <0. 05)。观察组患者的无疾病进展时间为4. 1个月,总生存时间为6. 3个月,对照组患者分别为1. 8个月和3. 2个月,两组比较,差异均有统计学意义(均P <0. 05)。观察组患者以Ⅰ～Ⅱ级不良反应占多数,经对症干预后明显改善;Ⅲ～Ⅳ级不良反应占少数,下调剂量及服用对症药物治疗后缓解。所有患者均未出现因不良反应终止治疗的事件,无治疗相关死亡病例。结论晚期肺腺癌患者采用阿帕替尼治疗具有较好的临床效果,且能改善患者生存时间,不良反应可以耐受,值得临床进一步推广。

Objective To investigate the clinical efficacy and safety of apatinib in the treatment of advanced lung adenocarcinoma.Methods A total of 110 patients with advanced lung adenocarcinoma were selected and were divided into an observation group and a control group at Liyang People’s Hospital from July2016 to June 2018.The observation group(58 patients)was given apatinib and the control group(52 patients)was given supportive treatment.The clinical efficacy and medication safety were compared between the two groups.Results The objective response rate(ORR)and disease control rate(DCR)was 13.8%and 58.6%,for the observation group,which was significantly higher than 0 and 13.4%of the control group(all P<0.05).The median progression-free period(PFS)was 4.1 months,the median total generation period(OS)was 6.3 months,the median PFS was 1.8 months and OS was 3.2 months for the control group(all P<0.05).The primary adverse reactions were gradeⅠ~Ⅱand could be alleviated after symptomatic treatment.Adverse reactions of gradeⅠ~Ⅱwere rare and could be improved by reducing the dose and using appropriate agents.No therapy discontinuation induced by adverse reactions occurred.No therapy associated motality occurred.Conclusion Apatinib has a good clinical efficacy for advanced lung adenocarcinoma and can improve the overall survival rate.Adverse reactions are tolerable and it deserves further clinical promotion.